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OBJECTIVE:
 
 To evaluate the impact of amlodipine
treatment on hospital utilization and costs.
 
METHODS:
 
 Hospital record data from the PRAISE
study were analyzed for 421 patients (amlodipine, 209;
placebo, 212) with nonischemic heart failure. Reason for
admission was encoded according to the ICD-9-CM and
a diagnosis related group (DRG) was assigned. Hospital-
ization costs were estimated from a DRG-based per-diem
cost of hospitalization multiplied by hospital length of
stay. Cost of amlodipine therapy was estimated from the
average wholesale price at the end of the study.
RESULTS: Treatment with amlodipine versus placebo
significantly delayed time to first hospitalization (447 
26 days versus 315  18 days [means  standard errors];
p  0.0139). Although both treatment groups showed a
similar number of hospital admissions per patient per
year (1.33  0.17 [amlodipine] versus 1.41  0.13 [pla-
cebo]; p  0.72), amlodipine showed a trend toward re-
duced hospital length of stay and costs (hospitalization
1.17 days less per year [p  0.13] than placebo at a cost
of $1098 less per person per year [p  0.09]). In addi-
tion, significantly fewer amlodipine patients were admit-
ted for unexplained cardiac arrest and ventricular ar-
rhythmias (odds ratio 0.497 [p  0.004]).
CONCLUSIONS: This analysis suggests that, in patients
with nonischemic heart failure, treatment with amlodipine
can delay time to hospitalization after starting treatment,
may reduce overall hospital utilization and costs, and may
reduce admissions related to ventricular arrhythmias. The
estimated reduction of $1098 per year in hospital costs
would more than offset the amlodipine treatment cost of
approximately $700 per year.
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OBJECTIVES: To study the glycoprotein IIb/IIIa inhibi-
tor abciximab (AB) in the actual use (uncontrolled) set-
ting.
METHODS: The study evaluated 291 patients who did
(n  145) or did not (n  146) receive AB as adjunct
treatment for PTCA at eight US academic centers. Based
on product labeling, all patients were eligible to receive
AB. Data came from hospital records and 6-month fol-
low-up interviews.
RESULTS: Most patients (87%) were treated by physi-
cians who chose AB in some but not others. Previous MI
(by history or as PTCA indication) and urgent admission
status were more common (p  0.05) in the AB group,
while angina unresponsive to medical therapy (ANGU)
and restenosis as indications for the PTCA were more
common (p  0.05) in the non-AB group. Bleeding and
other complications were comparable between the two
groups. Six-month data were: AB (n  145), No AB (n 
146) and P-value where Deaths were 6, 2, NS; Non-Fatal
MI were 12, 12, NS; Revascularization were 25, 23, NS;
and Other Cardiac Hospitalization were 17, 29, 0.057,
respectively. ANGU (OR, 2.26, p  0.02) and AB and
stents (OR, 0.61, p  0.04) affected other cardiac hospi-
talizations (e.g., CHF, arrhythmia). The combination of
AB and stents seemed to provide the best results for pre-
venting other cardiac hospitalizations.
CONCLUSION: Within labeled indications, physicians
seemed to select AB use based on certain patient charac-
teristics. The number of patients requiring subsequent
cardiac-related hospitalizations after 6 months tended to
be less in the abciximab-treated patients providing eco-
nomic offsets. Further studies are warranted to validate
these observations and the implications for healthcare re-
imbursement and practice guidelines.
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OBJECTIVE:
 
 The aim of this study was to estimate the
proportion of strokes occurring among hypertensive pa-
tients in The Netherlands attributable to under-treatment
of hypertension.
METHODS: The baseline data reported in this study
were collected in two population-based studies. Approxi-
mately 45,000 men and women aged 20 years and over
were examined in these studies. In all participants, blood
pressure, serum lipid levels, weight, and height were mea-
sured, and all respondents completed a questionnaire on
cardiovascular risk factors and current use of medication.
For the classification of under-treatment, the Dutch
guidelines for management of hypertension were used
(pharmacological treatment when diastolic blood pres-
sure [DBP] is between 100 and 105 mmHg and one or
more cardiovascular risk factors are present, or when the
systolic blood pressure [SBP] is between 160 and 180
mmHg and one or more cardiovascular risk factors are
present, or when DBP  105 mmHg, or when SBP  180
mmHg; treatment goal is a DBP  90 mmHg and a SBP 
160 mmHg). Information on fatal and non-fatal strokes
during follow-up were obtained through patient records
from general practitioners.
RESULTS: Of the subjects, 3168 were hypertensive. Sub-
jects who were not in need of pharmacological treatment
according to the guidelines and subjects with missing
data were excluded. Follow-up was complete for 2369
(91%) of the 2616 remaining subjects. Mean duration of
follow-up was 4.6 years. Compared to treated and con-
trolled hypertension, the adjusted relative risks of stroke
were 1.30 [95% CI 0.70–2.44] and 1.76 [95% CI 1.05–
2.94] for treated and uncontrolled hypertension, and un-
treated hypertension that should be treated, respectively.
Among hypertensives the proportion of strokes attribut-
able to under-treatment of hypertension was about 28%.
CONCLUSION: Improvement of control of hyperten-
sion among treated hypertensives, detection of hyperten-
sion, and adherence to the current guidelines on the man-
agement of hypertension might prevent a considerable
proportion of the incident strokes among hypertensives.
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The long-term prognostic influence of left ventricular sys-
tolic function (LVERSUSF) in diagnosing patients with con-
gestive heart failure (CHF) has been widely documented.
However, the short-term prognostic significance of
LVERSUSF on early hospital readmission for CHF is lim-
ited.
OBJECTIVES: The study purpose was to examine the in-
fluence of LVERSUSF on 90-day readmission for CHF.
METHODS: Medical records were reviewed for all pa-
tients with a principle diagnosis of CHF discharged alive
from January 1 through June 30, 1997 at an urban public
hospital. LVERSUSF assessments within 6 months prior to
discharge were used to classify patients as normal LVER-
SUSF or left-ventricular (LV) systolic dysfunction.
RESULTS: Among 387 patients, 303 (78.3%) had
6-month assessments of LVERSUSF. Among patients
with LVERSUSF assessments, 207 patients (68.3%) had
LV systolic dysfunction and 96 patients (31.7%) had
normal LV systolic function. A total of 54 (26.1%) of the
207 patients with LV systolic dysfunction were readmit-
ted for CHF within 90 days, versus 13 (13.5%) of the 96
patients with normal LVERSUSF that were readmitted
(p  0.01). Multivariate logistic regression analysis (in-
cluding: age, gender, prior history of CHF, comorbidities,
NYHA class, medication adherence) showed 90-day read-
mission for CHF was more likely in patients with LV sys-
tolic dysfunction than in those with normal LVERSUSF af-
ter adjusting for other identified risk factors (p  0.05).
CONCLUSIONS: LV systolic dysfunction appears to in-
crease the likelihood of 90-day readmission among pa-
tients with CHF. The findings underscore the ability of
LVERSUSF to stratify patients hospitalized for CHF and
suggest potential usefulness in aiding management by
identifying higher risk patients.
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OBJECTIVE:
 
 To determine inpatient resource use, cost,
and major cost drivers for idiopathic Parkinson’s disease
(PD).
METHODS: A retrospective study, evaluating patients ad-
mitted at a large academic medical center between July
1994 and June 1997 with a primary or secondary diagnosis
of PD. Average length of stay (ALOS), resource use, institu-
tional cost (including overhead), demographics, and admis-
sion severity information was extracted from the inpatient
cost accounting system. Resources and costs were then
grouped into categories based on type of service provided.
RESULTS: Sixteen patients with primary diagnosis
(PDX) and 378 patients with secondary diagnosis (SDX)
of PD were identified. Of the 378 SDX patients, only 54
patients were assumed to have a PD-related primary di-
agnosis and were included in the analysis. Although the
PDX group had higher admission severity scores than the
